Skip to content Skip to footer

Biotech & Healthcare

HomeBiotech & Healthcare

Business presenters at an investor conference stand beside a screen reading “Apple and Amwell Signal a New Premium Cycle for Tech and Digital Health,” highlighting integrated wearables, virtual-care expansion and data-driven insights.

Apple and Amwell Signal a New Premium Cycle for Tech and Digital Health -( $AAPL $AMWL $DELL $HPE $MSFT $TSLA )

by John F. Heerdink, Jr. 5 days ago

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026

Surreal financial illustration depicting Amwell’s potential U.S. Department of Veterans Affairs digital-health opportunity: a luminous “Letter of Intent” scroll marked “Amwell–VA Partnership,” a rising green arrow shaped like a fountain pen, “VA $AMWL” lettering, healthcare symbols, documents, and a winding road toward a futuristic city beneath a star-filled sky.

Amwell’s VA Letter of Intent Could Mark a Defining Turn for $AMWL

by John F. Heerdink, Jr. September 8, 2026

Digital Nasdaq billboard in Times Square highlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX), its Nasdaq Global Select Market upgrade, and the upcoming eosinophilic esophagitis clinical-data catalyst.

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. September 8, 2026

Illustration of an older man with Parkinson’s symptoms beside a laboratory researcher holding a syringe, with a large brain diagram showing dopamine pathways, sustained drug release, motor control, and Serina Therapeutics’ Parkinson’s disease drug-delivery innovation.

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026

Investor-themed graphic showing Tribe Public and ACOG logos above a rising green-and-gold stock chart, dollar signs, and the Zunveyl (benzgalantamine) 5 mg, 10 mg, and 15 mg branding against a modern city backdrop.

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

by John F. Heerdink, Jr. September 6, 2026

Illustrated investor infographic showing Modular Medical’s Pivot insulin delivery system helping diabetes patients move beyond traditional barriers to pump adoption. On the left, patients face injection pens, conventional pump complexity, cost concerns, and uncertainty; on the right, Pivot’s simple tubeless patch-pump design leads toward a growing market of converted pump users, with upward-growth arrows and active patients.

Modular Medical’s Pivot Launch Could Turn Diabetes Care’s “Almost Pumpers” Into a New Growth Market -( $MDT $MODD $PODD $TNDM )

by John F. Heerdink, Jr. September 5, 2026

Modular Medical’s Revenue Pivot: Why a Focused Launch Could Put $MODD on Wall Street’s Radar – Join Sept. 4 Tribe CEO Webinar

by John F. Heerdink, Jr. September 2, 2026

Comic-book-style illustration of a confident superhero in a teal suit with an “R” molecular symbol flying above a modern city skyline. Large headline text reads “Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention,” while surrounding signs reference Revolution Medicines, RVMD stock, innovation, cancer breakthrough and oncology leadership.

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

by John F. Heerdink, Jr. September 1, 2026

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026